Compare VTGN & AIRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VTGN | AIRE |
|---|---|---|
| Founded | 1998 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8M | 11.5M |
| IPO Year | 2014 | 2023 |
| Metric | VTGN | AIRE |
|---|---|---|
| Price | $0.24 | $1.56 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 3 |
| Target Price | $0.90 | ★ $1.30 |
| AVG Volume (30 Days) | ★ 716.8K | 93.8K |
| Earning Date | 06-16-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.34 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,518,498.00 |
| Revenue This Year | $124.49 | $129.06 |
| Revenue Next Year | $353.99 | $83.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 376.42 |
| 52 Week Low | $0.20 | $0.16 |
| 52 Week High | $5.14 | $3.98 |
| Indicator | VTGN | AIRE |
|---|---|---|
| Relative Strength Index (RSI) | 41.27 | 50.17 |
| Support Level | $0.23 | $1.29 |
| Resistance Level | $0.32 | $1.64 |
| Average True Range (ATR) | 0.02 | 0.14 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 31.67 | 44.23 |
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
ReAlpha Tech Corp is a real estate technology company. The group is engaged in an end-to-end commission-free homebuying platform. It develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for the analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability. The company's reportable segments are Homebuying Services and the Technology Services segment.